Company profile

Nachum Shamir
Incorporated in
Fiscal year end
IRS number

LMNX stock data



7 May 19
21 Jul 19
31 Dec 19


Company financial data Financial data

Quarter (USD) Mar 19 Dec 18 Sep 18 Jun 18
Revenue 82.41M 81.13M 72.45M 79.58M
Net income 2.96M -2.3M 1.74M 5.67M
Diluted EPS 0.07 -0.05 0.04 0.13
Net profit margin 3.59% -2.83% 2.40% 7.12%
Operating income -3.58M 968K 3.75M 7.86M
Net change in cash -14.75M -70.45M 7.9M 10.34M
Cash on hand 61.69M 76.44M 146.89M 139M
Cost of revenue 36.6M 32.79M 28.19M 30.27M
Annual (USD) Dec 18 Dec 17 Dec 16 Dec 15
Revenue 315.82M 306.57M 270.64M 237.71M
Net income 18.51M 29.42M 13.81M 36.86M
Diluted EPS 0.41 0.67 0.32 0.86
Net profit margin 5.86% 9.60% 5.10% 15.51%
Operating income 27.85M 37.15M 20.99M 37.36M
Net change in cash -50.67M 33.66M -35.09M 36.85M
Cash on hand 76.44M 127.11M 93.45M 128.55M
Cost of revenue 120.33M 107.53M 90.98M 69M

Financial data from Luminex earnings reports

Financial report summary

Management Discussion
  • Total revenue was $82.4 million for the three months ended March 31, 2019, down slightly from $82.7 million for the comparable period in 2018. The Company experienced a decrease in our non-automated assay revenue, mainly attributable to the decrease in LabCorp sales. These decreases were largely offset by the addition of our newly acquired flow cytometry business, which comprised 14% of total revenue in the first quarter of 2019, as well as increases in our automated assay revenue. Non-automated assay revenue comprised 48% of total assay revenue for the three months ended March 31, 2019 compared to 68% for the comparable period in 2018. Automated assay revenue, which consists of VERIGENE and ARIES® assays, grew 15% to more than $17.1 million for the three months ended March 31, 2019 from the comparable period in 2018.
Content analysis ?
H.S. sophomore Avg
New words: absolute, achieve, added, adding, affiliate, affordable, agreed, answer, area, attaching, authorization, benchtop, bind, biochemical, biomarker, borrowing, bringing, capture, captured, cease, cell, CellStream, centered, challenge, coated, color, colored, commencement, competing, consecutive, counting, create, customizable, cytometer, database, derived, discount, displayed, distinctly, driver, dye, easyCyte, ELISA, engineering, enzymatic, escalation, FlowSight, fluorescence, fluorescent, foregoing, Gen, highest, hour, ImageStream, immunologic, implicit, InCyte, inexpensive, injected, innovative, IRS, KgaA, laser, legislation, lighter, magnetic, maximum, mentioned, Merck, merit, microarray, microcapillary, microscopy, microsphere, microtiter, milestone, MilliporeSigma, mixture, Muse, nonrecurring, package, panel, particle, percent, plant, plate, polystyrene, preliminary, produce, reassessing, recruit, reliance, rent, retired, scalable, signature, simple, simplified, slightly, solution, space, spatial, speed, spite, stored, talent, technical, tenant, track, trend, tube, type, underway, versatile, vesting, viability, Washington, wholly
Removed: annually, AOCI, arise, ASU, audit, Australian, backed, bought, Bulletin, calculate, claimed, commercializing, commit, comparative, constrained, content, Cystic, declined, deemed, delivery, depending, depreciation, disposable, diversity, eliminating, evaluated, exceeded, extension, fewer, field, fifteen, finalized, forecasted, fourth, frequently, fulfillment, functionality, GILTI, handling, impractical, incorporated, industry, installation, integrated, interpretation, law, marketable, maturity, minimum, month, mortgage, negotiated, October, offered, originally, permanent, policy, practice, prepay, prepayment, principally, promise, promissory, purpose, reclassified, reclassify, recognizing, reduce, refine, refinement, registrant, reinvestment, relevant, remeasured, remeasurement, represented, requirement, restated, reversal, reverse, SAB, secondary, settled, shipment, shipped, shown, sourced, step, stranded, temporary, Topic, trading, treat, treated, twenty, ultimate, ultimately, understanding, unit